EU-GMP Certification for a Canadian Cannabis Facility in 2026

Start with the legal mechanics, because they explain why the process takes as long as it does. Under Article 46(f) of Directive 2001/83/EC, an EU manufacturer or importer must confirm that any active substance it uses was made in line with GMP. Dried cannabis flower entering Germany is treated as an active substance. The German importer, which holds an import licence under Section 72 of the Arzneimittelgesetz (AMG), therefore has to prove the Canadian site meets GMP. In practice that proof is a GMP certificate from a competent authority that has physically inspected the site.

That authority is never Health Canada. Canadian Licensed Producers operate under Part 5 of the Cannabis Regulations, known as Good Production Practices (GPP). GPP is a real quality framework: standard operating procedures under section 80, sanitation under section 87, a Quality Assurance Person who approves every lot under section 88, and mandatory testing under sections 90 to 92. What it is not is GMP. Health Canada does not inspect cannabis facilities against EudraLex Volume 4 and does not issue GMP certificates for cannabis. There's no Canadian document a German authority will accept as equivalent.

Who actually inspects a Canadian site

In Germany, GMP inspections are run by the state (Land) medicines authorities, coordinated nationally through the ZLG. The application is filed by the German importer or manufacturer with its local authority, which then schedules a third-country inspection of your Montreal, Moncton or Kelowna facility. BfArM handles the narcotics side (the MedCanG permits and per-shipment import authorisations), not the GMP inspection itself. Other member-state authorities, including Portugal's Infarmed, Denmark's DKMA and Malta's Medicines Authority, have also inspected overseas cannabis sites.

Part II, Annex 7 and the drying question

Two parts of EudraLex apply. Part II covers active substances, which is how flower is classified. EU GMP Annex 7 covers herbal medicinal products and draws the line between GACP (cultivation, harvest, initial sorting) and GMP (everything after). Since Hesse's June 2026 guidance treated controlled drying as a critical manufacturing step, that line has moved earlier in the process for German-bound flower. We covered the details in our piece on Germany's GMP washing crackdown. The practical consequence for a certification project is simple: your drying rooms, curing protocol and trimming line are now inside the inspection scope, not outside it.

Every Canadian LP that has earned a certificate has walked roughly the same sequence. We call it the 7-Stage Canadian EU-GMP Path. The stages are fixed. The time spent in each is where projects diverge.

1. Gap assessment against EudraLex. Compare your GPP system line by line with Part II, Annex 7, Annex 11 (computerised systems) and Annex 15 (qualification and validation). Typical gaps for a GPP-only site: no formal Pharmaceutical Quality System, no Site Master File, unvalidated drying and analytical methods, no environmental monitoring programme, and supplier qualification that stops at a purchase order.
2. Secure a sponsoring EU partner. You cannot apply on your own. A German importer with a Section 72 AMG licence (or an EU manufacturer with a manufacturing and import authorisation) files the inspection request with its competent authority. Choose this partner early, because their authority's workload sets your inspection date.
3. Remediate and document. Write and implement the Pharmaceutical Quality System: deviation and CAPA management, change control, self-inspection, training records, data integrity controls, a stability programme, and validated cleaning. Draft the Site Master File. Qualify the facility, utilities and equipment (IQ/OQ/PQ). This stage consumes most of the calendar.
4. Align batch release with the EU Qualified Person. Your Quality Assurance Person still releases under section 88 of the Cannabis Regulations, but the EU Qualified Person will re-release in Europe against your batch file. Build the file to the QP's standard now, and put the shared responsibilities into a quality agreement.
5. Mock inspection. Have an independent EU-GMP auditor run a full inspection simulation, including a data walkthrough of two or three complete batches from seed to shipment. Close every finding before the real inspectors book flights.
6. Regulatory inspection. Expect a small inspection team on site for three to five days. They'll interview your QAP and production leads, pull batch records and watch a trimming shift. They'll also test your document control by asking for a specific SOP version from eighteen months ago.
7. Close findings and receive the certificate. Findings are graded critical, major or other. You submit a CAPA response with evidence, and the authority may request further documentation or a follow-up visit. Once no critical or major findings remain open, the certificate is issued and published to EudraGMDP. Most certificates carry a three-year validity tied to the inspection date, after which re-inspection is due.

One detail catches Canadian teams off guard at stage 3. GPP already requires your Quality Assurance Person to approve every lot, so many LPs assume their release process is done. Inspectors don't evaluate whether release happens. They evaluate whether the record of release would let a stranger reconstruct every decision. That's a documentation depth most GPP systems were never built to reach.

Public disclosures from Canadian LPs give a more honest timeline than any consultant's brochure. Organigram applied for EU-GMP at its Moncton campus in November 2023, hosted a preliminary audit in February 2024, completed the certification audit in November 2024, and was still submitting documentation to close major findings in April 2026. As of the company's August 2026 results, the certificate remained pending with no confirmed date. That's 33 months and counting. Tilray, by contrast, told investors in August 2026 that its Quebec facility expects certification within 12 months. The company already runs certified sites in Portugal and Germany, so it can transplant a working quality system.

Canadian regulatory consultancies put the range at 12 to 24 months for a facility starting from a mature GPP system. Our own reading of the market is that 18 months is a realistic median for an indoor facility with disciplined records. The spread is driven almost entirely by how much remediation stage 3 demands.

The five findings that add months

• Microbial load out of specification. Organigram cited flower pass rates on microbial counts as an active constraint on European supply. If your product routinely relies on irradiation to meet the Ph. Eur. limits, inspectors will ask why the upstream process can't control it.
• Unvalidated analytical methods. Potency and contaminant methods must be validated to ICH standards, and your third-party lab's ISO/IEC 17025 accreditation doesn't substitute for method validation on your specific matrix. Our guide to export testing requirements across four markets lists the panels involved.
• Environmental monitoring gaps. Viable and non-viable particle monitoring in drying, curing and packaging rooms, with alert and action limits and trended data. GPP doesn't require it. GMP inspectors expect it.
• Supplier qualification. Growing media, nutrients, packaging and the contract lab all need documented qualification, approved supplier lists and periodic re-evaluation.
• Data integrity. Audit trails on environmental controllers, balances and the LIMS. Paper records with correction fluid or undated changes are a near-guaranteed major finding.

Budget for the inspection cycle itself, not just the inspection. The gap between a preliminary audit and a closed certificate is where Organigram spent most of its 33 months. Each round of CAPA correspondence with a German state authority can take a quarter.

Not every Canadian LP needs its own EU-GMP certificate to sell abroad. Three routes exist in 2026, and each carries a different exposure profile.

The GACP-only route built the German market. Flower cultivated and dried in Canada under GACP shipped to a European facility that packaged and released it under GMP. That model still operates. The Hessian reading of Annex 7, though, means importers now want evidence that drying and trimming happened under GMP-equivalent control, which pulls Canadian sites back toward a full certificate anyway.

Australia works differently. The TGA holds a mutual recognition agreement with Canada for medicinal product GMP inspections, but that agreement only helps if Health Canada inspected you against GMP, which for cannabis it doesn't. Canadian LPs therefore use the Compliance Verification pathway, submitting an EU authority's inspection report as evidence, or accept a TGA on-site inspection. Either way your Australian sponsor applies and maintains the clearance, and every batch must meet TGO 93. An EU-GMP certificate earned for Germany is the single most reusable piece of evidence you can carry into that process.

Deciding whether to pursue your own certificate

Run the numbers on three questions. First, does your export volume justify an 18-to-36-month project plus a permanent uplift in quality headcount? Second, is your German partner willing to sponsor the inspection, and how backed up is their state authority? Third, can your facility meet Ph. Eur. microbial limits without relying on remediation, since that's the finding most likely to stall closure? If all three answers are yes, the certificate is the only route whose regulatory footing improved in 2026 rather than weakened.

AlphaLeaf is a Health Canada Licensed Producer growing indoor, hand-trimmed cannabis flower in Montreal. We hold export authorisation under the Cannabis Act and test every batch through an ISO/IEC 17025-accredited laboratory. Our batch traceability and quality documentation are built for the review German importers and their Qualified Persons run before release into the medical channel.

If you're mapping your own certification path or looking for a Canadian supplier whose records are already built for a European batch file, contact our team.

Can Health Canada issue an EU-GMP certificate for a cannabis facility?

No. Health Canada regulates cannabis Licensed Producers under Part 5 of the Cannabis Regulations (Good Production Practices), not GMP, and does not issue GMP certificates for cannabis. Only an EU member-state medicines authority can issue an EU-GMP certificate, and it does so after inspecting the Canadian site directly.

How long does EU-GMP certification take for a Canadian cannabis LP?

Consultancies quote 12 to 24 months from gap assessment to certificate for a facility with a mature GPP system. Public disclosures show wider variance. Organigram applied in November 2023 and was still closing findings in 2026. Tilray expects its Quebec site to be certified within about 12 months of its August 2026 update. A realistic planning median is around 18 months, with stage 3 remediation the main variable.

Who applies for the inspection of a Canadian cannabis facility?

Not the Canadian LP. The application is filed by an EU importer or manufacturer, typically a German company holding a Section 72 AMG import licence, with its state medicines authority. That authority then schedules a third-country inspection of the Canadian site. You need that sponsoring partner in place before any inspection can be booked.

Is GACP certification enough to export cannabis flower to Germany in 2026?

It was the standard route: GACP flower shipped to an EU-GMP processor for release. Since Hesse's June 2026 guidance classified controlled drying as a critical GMP step, German importers increasingly want evidence that drying and trimming took place under GMP control. GACP still matters, but relying on it alone carries more regulatory risk than it did in 2025.

Does an EU-GMP certificate help with exporting cannabis to Australia?

Yes. Australia's TGA accepts an EU authority's inspection outcome through its Compliance Verification pathway when assessing GMP clearance for an overseas site. Health Canada does not inspect cannabis facilities to GMP, so the Canada-Australia mutual recognition agreement cannot be used for cannabis flower. An EU-GMP certificate is usually the strongest evidence a Canadian LP can offer its Australian sponsor.